Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878980 | 0.86 | BTK (0.35) | BTKFGFR1 | |
| SCHEMBL394534 | 0.85 | ABL1 (0.34) | BTKFGFR1 | |
| SCHEMBL2925835 | 0.79 | PDE10A (0.37) | CA12CA1CA2CA9FGFR1 | |
| SCHEMBL2975858 | 0.78 | HDAC3 (0.40) | BTKFGFR1 | |
| SCHEMBL2927723 | 0.78 | CA12 (0.30) | CA12CA1CA2CA9FGFR1 | |
| SCHEMBL3963838 | 0.78 | PIK3CD (0.41) | CA1CA2CA9 | |
| SCHEMBL3968806 | 0.77 | CA2 (0.42) | BTKCA2FGFR1 | |
| SCHEMBL3969215 | 0.75 | ESR1 (0.38) | — | |
| SCHEMBL1337994 | 0.74 | MEN1 (0.34) | FGFR1 | |
| SCHEMBL3967424 | 0.73 | MAPT (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101563342-B | Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer | LILLY CO ELI | 2012-09-05 | — | — | CN | disclosed |
| CN-101568539-B | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | LILLY CO ELI | 2012-04-25 | — | — | CN | disclosed |
| EP-2125794-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2125793-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-04-01 | — | — | US | disclosed |
| CN-101568539-A | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | LILLY CO ELI (US) | 2009-10-28 | — | — | CN | disclosed |
| CN-101563342-A | Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer | LILLY CO ELI (US) | 2009-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, AURKC, BUB1B | BTK 1568/4885CA12 3247/4885CA1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.